| abstract |
The invention provides a combination of a compound having the formula (0) and two or more additional anti-cancer agents or salts or tautomers or N-oxides or solvates thereof; wherein X is an R1-A-NR4- group or a 5- or 6-membered heterocyclic or carbocyclic ring; A is a bond, SO2, C = O, NRg (C = O) or O (C = O), wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; And it is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (for example fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-hydrocarbonylamino of C1-4, and carbocyclic or heterocyclic groups having 3 to 12 members in the ring, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (for example methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (for example fluorine), hydroxy or C1-4 alkoxy (for example methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (for example fluorine), hydroxy or C1-4 alkoxy (for example methoxy). |